Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.
Ferreri AJM, Calimeri T, Ponzoni M, Curnis F, Conte GM, Scarano E, Rrapaj E, De Lorenzo D, Cattaneo D, Fallanca F, Nonis A, Foppoli M, Lopedote P, Citterio G, Politi LS, Sassone M, Angelillo P, Guggiari E, Steffanoni S, Tarantino V, Ciceri F, Bordignon C, Anzalone N, Corti A. Ferreri AJM, et al. Among authors: de lorenzo d. Blood Adv. 2020 Aug 11;4(15):3648-3658. doi: 10.1182/bloodadvances.2020002270. Blood Adv. 2020. PMID: 32766857 Free PMC article. Clinical Trial.
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.
Ferreri AJM, Sassone M, Angelillo P, Zaja F, Re A, Di Rocco A, Spina M, Fabbri A, Stelitano C, Frezzato M, Volpetti S, Zambello R, Rusconi C, De Lorenzo D, Scarano E, Arcari A, Bertoldero G, Nonis A, Calimeri T, Perrone S, Cecchetti C, Tarantino V, Steffanoni S, Foppoli M, Ciceri F, Ponzoni M. Ferreri AJM, et al. Among authors: de lorenzo d. Hematol Oncol. 2020 Aug;38(3):257-265. doi: 10.1002/hon.2742. Epub 2020 May 5. Hematol Oncol. 2020. PMID: 32356913 Clinical Trial.
MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM, Calimeri T, Lopedote P, Francaviglia I, Daverio R, Iacona C, Belloni C, Steffanoni S, Gulino A, Anghileri E, Diffidenti A, Finardi A, Gagliardi F, Anzalone N, Nonis A, Furlan R, De Lorenzo D, Terreni MR, Martinelli V, Sassone M, Foppoli M, Angelillo P, Guggiari E, Falini A, Mortini P, Filippi M, Tarantino V, Eoli M, Ciceri F, Doglioni C, Tripodo C, Locatelli M, Cangi MG, Ponzoni M. Ferreri AJM, et al. Among authors: de lorenzo d. Br J Haematol. 2021 May;193(3):497-505. doi: 10.1111/bjh.17357. Epub 2021 Feb 23. Br J Haematol. 2021. PMID: 33620087 Clinical Trial.
Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218.
Timon G, Ciardo D, Bazani A, Marvaso G, Riva G, Volpe S, Rojas DP, Renne G, Petralia G, Zerini D, Fodor C, Dicuonzo S, Maestri D, Pansini F, Cambria R, Cattani F, Golino F, Scroffi V, De Lorenzo D, De Cobelli O, Orecchia R, Jereczek-Fossa BA. Timon G, et al. Among authors: de lorenzo d, de cobelli o. Br J Radiol. 2018 Sep;91(1089):20160725. doi: 10.1259/bjr.20160725. Epub 2018 May 23. Br J Radiol. 2018. PMID: 29750539 Free PMC article. Clinical Trial.
Rationale and protocol of AIRC IG-13218, short-term radiotherapy for early prostate cancer with concomitant boost to the dominant lesion.
Timon G, Ciardo D, Bazani A, Garioni M, Maestri D, De Lorenzo D, Pansini F, Cambria R, Rondi E, Cattani F, Marvaso G, Zerini D, Vischioni B, Ciocca M, Russo S, Molinelli S, Golino F, Scroffi V, Rojas DP, Fodor C, Petralia G, Santoro L, De Cobelli O, Orecchia R, Jereczek-Fossa BA. Timon G, et al. Among authors: de lorenzo d, de cobelli o. Tumori. 2016 Oct 13;102(5):536-540. doi: 10.5301/tj.5000547. Epub 2016 Aug 5. Tumori. 2016. PMID: 27514314 Clinical Trial.
Targeting the Jak/Signal Transducer and Activator of Transcription 3 Pathway with Ruxolitinib in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa-Squamous Cell Carcinoma.
Jacków J, Rami A, Hayashi R, Hansen C, Guo Z, DeLorenzo D, Pappalardo A, Alvarez Cespedes D, Kim AL, Perez-Lorenzo R, Owens DM, Christiano AM. Jacków J, et al. J Invest Dermatol. 2021 Apr;141(4):942-946. doi: 10.1016/j.jid.2020.08.022. Epub 2020 Oct 16. J Invest Dermatol. 2021. PMID: 33069729 Free article. No abstract available.
48 results